MacroGenics reported a FY 2025 net loss of USD 74.62 million, compared with a FY 2024 net loss of USD 66.97 million. FY 2025 total revenue was USD 149.5 million, down less than 5%, with contract manufacturing revenue of USD 52.63 million, which more than tripled on increased production for external clients. FY 2025 R&D expenses were USD 147.17 million, down 17%, driven by lower costs for terminated or sold programs and reduced manufacturing and IND-enabling spending for MGC028, partly offset by higher clinical trial costs for MGC026 and MGC028 and increased development costs for MGC030. FY 2025 SG&A expenses were USD 39.16 million, down 45% due to lower stock-based compensation and reduced professional fees. Cash, cash equivalents and marketable securities were USD 189.91 million at year-end, and management said cash runway guidance remains into late 2027 while it targets initial Phase 1 data for MGC026 in mid-2026 and MGC028 in the second half of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MacroGenics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603091601PRIMZONEFULLFEED9668479) on March 09, 2026, and is solely responsible for the information contained therein.
Comments